Search Within

Lisa Bodei

  1. "Joseph O'Donoghue"
Formats
  1. Journal Article (7)
  2. Meeting Abstract (5)
  3. Conference Paper (1)
Groups
  1. Medical Physics (13)
  2. Molecular Imaging and Therapy Service (13)
  3. Radiology, Department of (13)
  4. Sloan Kettering Institute Postdocs (13)
  5. Department of Medicine (8)
  6. Solid Tumor Oncology Division (8)

More Groups

People
  1. Joseph O'Donoghue (13)
  2. Diane Reidy (5)
  3. Neeta Pandit-Taskar (5)
  4. Simone Krebs (5)
  5. Wolfgang Weber (5)
  6. Jason Lewis (4)

More People

Years
  1. 2024 (2)
  2. 2023 (5)
  3. 2021 (1)
  4. 2020 (1)
  5. 2019 (2)
  6. 2018 (2)
Publications
  1. European Journal of Nuclear Medicine and Molecular Imaging (3)
  2. Journal of Nuclear Medicine (3)
  3. Clinical Cancer Research (1)
  4. Clinical Nuclear Medicine (1)
  5. International Journal of Radiation Oncology, Biology, Physics (1)
  6. Journal of Clinical Oncology (1)

More Publications

Publishers
  1. Society of Nuclear Medicine (3)
  2. Springer (3)
  3. Lippincott Williams & Wilkins (2)
  4. American Association for Cancer Research (1)
  5. American Society of Clinical Oncology (1)
  6. Elsevier Inc. (1)

More Publishers

Results (13)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Imaging with [(89)Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: A phase 1/2, first-in-human trial
    Journal Article

    Tendler, S.; Dunphy, M. P.; Agee, M.; O'Donoghue, J.; Aly, R. G.; Choudhury, N. J.; Kesner, A.; Kirov, A.; Mauguen, A.; Baine, M. K.; more...
    Lancet Oncology (2024)

    Fulltext@MSK | Save
  • How can radiopharmaceutical therapies reach their full potential? Improving dose reporting and phase I clinical trial design
    Journal Article

    Kiess, A. P.; O'Donoghue, J.; Uribe, C.; Bodei, L.; Hobbs, R. F.; Hesterman, J.; Kesner, A. L.; Sgouros, G.; on behalf of the RPT-TEC group
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A novel model-based planar reconstruction method for accurate activity distribution estimation for 225Ac-PSMA targeted alpha therapy
    Meeting Abstract

    Schmidtlein, C.; Ren, J.; Krol, A.; O'Donoghue, J.; Gifford, H.; Bodei, L.; Lafontaine, D.; Zechowy, D.; Xu, Y.
    Journal of Nuclear Medicine (2023)

    Fulltext@MSK | Save
  • Index lesion dosimetry for (177)Lu-PSMA-617 radiopharmaceutical therapy combined with stereotactic body radiotherapy in patients with oligometastatic castration-sensitive prostate cancer
    Meeting Abstract

    Grkovski, M.; O'Donoghue, J.; Imber, B.; Andl, G.; Tu, C.; Lafontaine, D.; Schwartz, J.; Thor, M.; Zelefsky, M.; Humm, J.; more...
    Journal of Nuclear Medicine (2023)

    Fulltext@MSK | Save
  • Lesion dosimetry for [(177)Lu]Lu-PSMA-617 radiopharmaceutical therapy combined with stereotactic body radiotherapy in patients with oligometastatic castration-sensitive prostate cancer
    Journal Article

    Grkovski, M.; O'Donoghue, J. A.; Imber, B. S.; Andl, G.; Tu, C.; Lafontaine, D.; Schwartz, J.; Thor, M.; Zelefsky, M. J.; Humm, J. L.; more...
    Journal of Nuclear Medicine (2023)

    Fulltext@MSK | Save
  • A phase 1, open-label, dose-ascending study to evaluate the safety and tolerability of the therapeutic radiopharmaceutical (131)I-MIP-1095 for the treatment of metastatic castration-resistant prostate cancer
    Journal Article

    Laccetti, A. L.; Bodei, L.; O'Donoghue, J. A.; Weber, W. A.; Morris, M. J.
    Clinical Nuclear Medicine (2023)

    Fulltext@MSK | Save
  • A pilot study of stereotactic body radiotherapy and (177)Lu-PSMA-617 for oligometastatic hormone sensitive prostate cancer
    Meeting Abstract

    Imber, B. S.; Bodei, L.; Humm, J.; Ionescu, A.; Wu, W.; Grkovski, M.; O'Donoghue, J.; Reddy, R. P.; Rimner, A.; Shasha, D.; more...
    International Journal of Radiation Oncology, Biology, Physics (2023)

    Fulltext@MSK | Save
  • A deblurring/denoising corrected scintigraphic planar image reconstruction model for targeted alpha therapy
    Conference Paper

    Schmidtlein, C. R.; Maroun, M.; Krol, A.; Gifford, H.; Li, S.; Bodei, L.; O'Donoghue, J.; Häggström, I.; Xu, Y.
    SPIE (2021)

    Fulltext@MSK | Save
  • Comparison of (68)Ga-DOTA-JR11 PET/CT with dosimetric (177)Lu-satoreotide tetraxetan ((177)Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy
    Journal Article

    Krebs, S.; O'Donoghue, J. A.; Biegel, E.; Beattie, B. J.; Reidy, D.; Lyashchenko, S. K.; Lewis, J. S.; Bodei, L.; Weber, W. A.; Pandit-Taskar, N.
    European Journal of Nuclear Medicine and Molecular Imaging (2020)

    Fulltext@MSK | Save
  • Phase I trial of well-differentiated neuroendocrine tumors (NETs) with radiolabeled somatostatin antagonist (177)Lu-satoreotide tetraxetan
    Journal Article

    Reidy-Lagunes, D.; Pandit-Taskar, N.; O'Donoghue, J. A.; Krebs, S.; Staton, K. D.; Lyashchenko, S. K.; Lewis, J. S.; Raj, N.; Gönen, M.; Lohrmann, C.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save